Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Long-term treatment with low doses of GW-9508-another GPR40 agonist-decreased circulating glucose and insulin levels significantly, which resulted in improvements in glucose intolerance in high fat diet-induced diabetic mice [58]
(PubMed) Bernhard W, Shunova A, Machann J, et al
ENDNOTES [1] This section primarily covers state laws enacted between October 2025 and mid-February 2026
The true deciding factors are: From a clinical standpoint, the selection between Mounjaro and Zepbound can be explained by: Insurance which one is on formulary Indication diabetes or obesity Manufacturers aid programs eligibility varies Drug supply occasional shortages impact one brand differently Prescribing habits Mounjaro prescribed to diabetics
The blood work tells another, often more important one
